Key Drivers
- Strong liquidity
- Negative margins
- Financing-dependent
AIAI Summary
GRAL has shifted from an approval‑option growth bet to a cash‑rich, execution‑dependent commercial company where near‑term value now hinges on demonstrable per‑test gross‑margin improvement and positive PMA/NHS readouts to avoid dilution or impairment, so investors should only add exposure if they can monitor clinical/regulatory milestones and require clear, repeatable unit economics before increasing position.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Negative margins
- •Financing-dependent
GRAL is liquid and conservatively capitalized with low leverage and strong cash/equity cushions, but suffers from severe negative gross margins, massive operating losses and negative free cash flow, forcing reliance on external financing.
Price Behavior
Key Price Behavior Insights:
- •Short‑term downtrend
- •Defined $43 low
- •Mid‑$50s reversal
GRAL is in a short‑term downtrend below its last‑month SMA after plunging from the ~95–105 area to the low‑$40s, with immediate support at $43 — failure to hold $43 keeps downside risk high while a rally above the mid‑$50s would signal a short‑term reversal.
Rapid collapse from ~95–105 into the low‑$40s between 2026‑02‑12 and 2026‑03‑13 indicating extreme volatility
Sentiment & News
Key News Insights:
- •Trial failure
- •Sharp stock drop
- •Legal probes
Grail's NHS‑Galleri trial miss spurred a ~50% stock collapse, surge in options activity and securities investigations despite rising Galleri revenue, a PMA submission and cash runway into 2030.
Expect sustained volatility and downside pressure until regulatory/clinical clarity and investigation outcomes restore investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings